Alan Lader
Directeur Technique/Scientifique/R&D chez CITIUS PHARMACEUTICALS, INC.
Profil
Alan Lader is currently the SVP, Head-Clinical Operations & Quality Assurance at Citius Pharmaceuticals, Inc. Previously, he worked as the Director-Clinical Operations at Ischemix, Inc. Lader received his undergraduate degree from Syracuse University, his graduate degree from Rensselaer Polytechnic Institute, and his doctorate from the University of South Carolina School of Medicine.
Postes actifs de Alan Lader
| Sociétés | Poste | Début |
|---|---|---|
| CITIUS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/03/2016 |
Anciens postes connus de Alan Lader
| Sociétés | Poste | Fin |
|---|---|---|
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Corporate Officer/Principal | - |
Formation de Alan Lader
| University of South Carolina School of Medicine | Doctorate Degree |
| Rensselaer Polytechnic Institute | Graduate Degree |
| Syracuse University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CITIUS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |